Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study PXN110748: An Efficacy and Safety Study of XP13512 [gabapentin enacarbil] Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN)

Next Previous
X
Search
Trial Profile

Study PXN110748: An Efficacy and Safety Study of XP13512 [gabapentin enacarbil] Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort

    • Most Recent Events

    • 03 May 2014 Results of an analysis of sensitivity analyses based on secondary endpoints presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 03 May 2014 Results of an analysis of sensitivity analyses based on the primary endpoint presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 07 Jun 2012 Results from this trial were used to support approval of gabapentin enacarbil for the treatment of postherpetic neuralgia in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top